Telomir Pharmaceuticals (TELO) Total Non-Current Liabilities (2022 - 2024)
Telomir Pharmaceuticals (TELO) posted Total Non-Current Liabilities of $180968.0 for Q4 2024, down 64.27% sequentially from $506479.0 in Q3 2024, and down 77.61% YoY from $808187.0 in Q1 2024.
Telomir Pharmaceuticals (TELO) Total Non-Current Liabilities (2022 - 2024) Analysis & Trends
Telomir Pharmaceuticals has reported Total Non-Current Liabilities for 3 years, with the latest figure at $180968.0 in Q4 2024.
- Quarterly Total Non-Current Liabilities fell 77.61% year-over-year to $180968.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $180968.0 (down 77.61% YoY) and the FY2024 annual result came in at $180968.0, down 77.61% from the prior year.
- Total Non-Current Liabilities fell to $180968.0 in Q4 2024 per TELO's latest filing, from $506479.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $808187.0 in Q4 2023 and troughed at $180968.0 in Q4 2024.
- A 3-year average of $462053.2 and a median of $441435.5 in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 99.94% in 2023, then plunged 77.61% in 2024.
- Over 3 years, Total Non-Current Liabilities stood at $404221.0 in 2022, then jumped by 99.94% to $808187.0 in 2023, then slumped by 77.61% to $180968.0 in 2024.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $180968.0, $506479.0, and $393814.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 180,968.00 |
| Sep 30, 2024 | 506,479.00 |
| Jun 30, 2024 | 393,814.00 |
| Mar 31, 2024 | 478,650.00 |
| Dec 31, 2023 | 808,187.00 |
| Dec 31, 2022 | 404,221.00 |